11N-806

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 11N-806
• 英文别名: (4-chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine；4-(4'-chlorophenyl)-amino-6,7-dimethoxyquinazoline；N-(4-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine
• 化学式: C₁₆H₁₄ClN₃O₂
• 分子量: 315.759
• InChiKey: LHGGYEWCVWOGFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  56.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  对氯苯胺 、 4-氯-6,7-二甲氧基喹唑啉 以 乙腈 为溶剂， 反应 24.0h， 以100%的产率得到11N-806
  参考文献：
  名称：

  Investigation of a novel molecular descriptor for the lead optimization of 4-aminoquinazolines as vascular endothelial growth factor receptor-2 inhibitors: Application for quantitative structure–activity relationship analysis in lead optimization

  摘要：

  We investigated the use of infrared vibrational frequency of ligands as a potential novel molecular descriptor in three different molecular target and chemical series. The vibrational energy of a ligand was approximated from the sum of infrared (IR) absorptions of each functional group within a molecule and normalized by its molecular weight (MDIR). Calculations were performed on a set of 4-aminoquinazolines with similar docking scores for the VEGFR2/KDR receptor. 4-Aminoquinazolines with MDIR values ranging 192-196 provided compounds with KDR inhibitory activity. The correlation of KDR inhibitory activity was similarly observed in a separate chemical series, the pyrazolo[1,5-a]pyrimidines. Initial exploration of this molecular descriptor supports a tool for rapid lead optimization in the 4-aminoquinazoline chemical series and a potential method for scaffold hopping in pursuit of new inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.037

文献信息

• Quinazoline formulations and therapeutic use thereof
  申请人：PARKER HUGHES INSTITUTE

  公开号：US20020111360A1

  公开（公告）日：2002-08-15

  Pharmaceutical compositions for parenteral administration of poorly soluble quinazoline compounds in the form of microemulsions or micellar solutions are described. The compositions are useful in treating patients suffering from cancer or having allergic reactions.

  描述了用于以微乳液或胶束溶液形式给予难溶性喹唑啉化合物的肌肉注射制剂。这些制剂对于治疗患有癌症或过敏反应的患者是有用的。
• Quinazolines and therapeutic use thereof
  申请人：Hughes Institute

  公开号：US20010016588A1

  公开（公告）日：2001-08-23

  Quinazoline compounds and methods for the treatment of cancer and for the treatment of allergic reactions.

  喹唑啉化合物及其在癌症治疗和过敏反应治疗中的方法。
• 4-Anilinequinazolines with adenosine-kiase inhibitor properties
  申请人：Franchini Gomes Kleber

  公开号：US20070060600A1

  公开（公告）日：2007-03-15

  The present invention relates to the use of 4-anilinoquinazoline derivatives as adenosine-kinase inhibitors. The present invention also relates to a method for protecting tissues and organs like heart, brain and kidneys affected by ischemia, and for treating heart insufficiency, myocardium infarct, arrhythmia, arterial hypertension, atherosclerosis, coronary artery restenosis after angioplasty, chronic renal insufficiency, cerebral vascular accident, and chronic inflanunatory diseases (e.g., rheumatoid arthritis). The present invention also relates to the compound 6,7-dimethoxy-4-(3′-N′,N′-dimethylaminoanilino)quinazoline, or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising it and use of such compound in the manufacture of a medicament for treating or preventing diseases or conditions that are benefited from the adenosine-kinase inhibition.

  本发明涉及使用4-苯胺基喹唑啉衍生物作为腺苷激酶抑制剂。本发明还涉及一种保护受缺血影响的心脏、脑和肾等组织和器官，并治疗心力衰竭、心肌梗塞、心律失常、动脉高血压、动脉粥样硬化、血管成形术后冠状动脉再狭窄、慢性肾功能不全、脑血管意外和慢性炎症性疾病（如类风湿性关节炎）的方法。本发明还涉及化合物6,7-二甲氧基-4-(3'-N',N'-二甲基氨基苯基)喹唑啉或其药学上可接受的盐、包含它的制药组合物以及使用该化合物制造治疗或预防从腺苷激酶抑制中受益的疾病或病情的药物的用途。
• Investigation of a novel molecular descriptor for the lead optimization of 4-aminoquinazolines as vascular endothelial growth factor receptor-2 inhibitors: Application for quantitative structure–activity relationship analysis in lead optimization
  作者：Joel K. Kawakami、Yannica Martinez、Brandi Sasaki、Melissa Harris、Wendy E. Kurata、Alan F. Lau

  DOI：10.1016/j.bmcl.2011.01.037

  日期：2011.3

  We investigated the use of infrared vibrational frequency of ligands as a potential novel molecular descriptor in three different molecular target and chemical series. The vibrational energy of a ligand was approximated from the sum of infrared (IR) absorptions of each functional group within a molecule and normalized by its molecular weight (MDIR). Calculations were performed on a set of 4-aminoquinazolines with similar docking scores for the VEGFR2/KDR receptor. 4-Aminoquinazolines with MDIR values ranging 192-196 provided compounds with KDR inhibitory activity. The correlation of KDR inhibitory activity was similarly observed in a separate chemical series, the pyrazolo[1,5-a]pyrimidines. Initial exploration of this molecular descriptor supports a tool for rapid lead optimization in the 4-aminoquinazoline chemical series and a potential method for scaffold hopping in pursuit of new inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.
• QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF
  申请人：Parker Hughes Institute

  公开号：EP1162974A1

  公开（公告）日：2001-12-19